Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
Autores da FMUP
Participantes de fora da FMUP
- Cleland, JG
- Girerd, N
- Bozec, E
- Rossignol, P
- Pellicori, P
- Cosmi, F
- Mariottoni, B
- Solomon, SD
- Pitt, B
- Pfeffer, MA
- Shah, AM
- Petutschnigg, J
- Pieske, B
- Edelmann, F
- Zannad, F
Unidades de investigação
Abstract
Filiações
Filiações não disponíveis
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Ferreira JP,Cleland JG,Girerd N,Bozec E,Rossignol P,Pellicori P,Cosmi F,Mariottoni B,Solomon SD,Pitt B,Pfeffer MA,Shah AM,Petutschnigg J,Pieske B,Edelmann F,Zannad F. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials. Eur. J. Heart Fail. 2023. 25. (1):p. 108-113. IF:18,200. (1).